ArticleBMC cancer2026
Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations in the BRCA1 and BRCA2 genes play a pivotal role in the pathogenesis of breast, ovarian, prostate, pancreatic, and several other cancers. Identification of these mutations is crucial for selecting patients eligible for targeted therapy. In Vietnam, large-scale data on BRCA1/2 mutation prevalence and clinical utility are limited. We aim to report the prevalence of BRCA1/2 mutations across different cancer types, evaluate the effectiveness of next-generation sequencing (NGS) in copy-number variant detection, and discuss the clinical significance of the findings.
methodsA total of 1,101 Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer underwent BRCA1/2 mutation test at Vinmec. The test utilized the AmoyDx BRCA-PRO KIT and the Illumina NextSeq 550 NGS platform. Copy-number variants were detected by NGS solely in blood-derived DNA samples and were systematically confirmed by MLPA.
resultsAmong 1,101 unselected patients with breast, ovarian, prostate, or pancreatic cancer, pathogenic BRCA1/2 variants were identified in 158 (14.35%), including 57/158 of ovarian, 78/158 triple‑negative, 16/158 of prostate, 4/158 of pancreatic and 3/158 HR-positive breast cancer. The mutation burden was highest in ovarian cancer and TNBC, where BRCA1 variants predominated over BRCA2 (40/57 BRCA1 vs 17/57 BRCA2 in ovarian cancer and 57/78 BRCA1 vs 21/78 BRCA2 in TNBC). Several BRCA1 truncating variants (c.4997dup, c.5251C > T, c.5335del) and recurrent BRCA2 loss‑of‑function variants were enriched in triple‑negative breast cancer (TNBC), with additional cases observed in ovarian, prostate, and pancreatic cancers. Notably, two heterozygous copy‑number losses were observed in our series: BRCA1 exon 2 deletion (three TNBC and one ovarian cancer) and BRCA2 exon 22-23 deletion (one TNBC and one prostate cancer).
conclusionsThis study provides one of the first large next-generation sequencing-based BRCA1/2 datasets in Vietnam, indicating a sizable subset of tumors with homologous recombination deficiency and potential sensitivity to PARP inhibitors and platinum‑based chemotherapy. These findings underscore the clinical utility of NGS‑based BRCA1/2 genotyping for therapeutic decision‑making and hereditary risk assessment across multiple tumor types and highlight the need for further research on long-term clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.